GlassScriptPhysician profile
Danxuan Long
NPI 1205098738
$3,013.53
in general payments reported to CMS, 2019-2025
31 companies · $802 in 2025
The $802 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $428 · 2020: $93.92 · 2021: $251 · 2022: $379 · 2023: $398 · 2024: $661 · 2025: $802.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,783 · Education: $78.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,782.50 |
| Education | $78.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,427.01 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $236.50 | 2019-2025 | Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.74 | 2019-2025 | Ofev |
| Actelion Pharmaceuticals US, INC. | $113.24 | 2019-2024 | Opsumit, Uptravi |
| Viatris Specialty LLC | $94.52 | 2025 | Yupelri |
| Lundbeck LLC | $85.68 | 2024-2025 | Vyepti, Rexulti |
| Insmed, INC. | $83.18 | 2019-2025 | Arikayce, Brinsupri |
| Grifols USA, LLC | $67.40 | 2019-2025 | Gamunex-C |
| Regeneron Healthcare Solutions, INC. | $64.11 | 2019-2025 | Dupixent |
| Neurelis, INC. | $55.42 | 2024-2025 | Valtoco |
| Neurocrine Biosciences, INC. | $51.58 | 2025 | |
| Smith+Nephew, INC. | $50.03 | 2025 | Stravix Pl, Oasis, Grafix Pl |
| Jazz Pharmaceuticals INC. | $48.35 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.33 | 2024-2025 | Eohilia, Entyvio |
| Electromed, INC. | $43.27 | 2024 | Smartvest |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz Pharmaceuticals, LLC | $40.60 | 2025 | Xeomin, Inbrija |
| Mallinckrodt Hospital Products INC. | $37.97 | 2025 | Acthar |
| Teva Pharmaceuticals USA, INC. | $37.53 | 2024-2025 | Austedo Xr, Austedo Xr |
| Ucb, INC. | $36.95 | 2024-2025 | Briviact, Nayzilam |
| Abbvie INC. | $32.35 | 2025 | |
| Amgen INC. | $28.88 | 2024 | Uplizna |
| Itamar Medical INC | $28.82 | 2025 | Watchpatone |
| 3b Medical, INC. | $27.58 | 2025 | Luna |
| Inspire Medical Systems, INC. | $23.42 | 2023 | Inspire |
| Vanda Pharmaceuticals INC. | $22.78 | 2025 | Ponvory |
| Csl Behring | $19.37 | 2024 | Hizentra |
| Vertex Pharmaceuticals Incorporated | $18.52 | 2025 | |
| Alexion Pharmaceuticals, INC. | $16.21 | 2019 | |
| Phathom Pharmaceuticals, INC. | $15.49 | 2024 | Voquezna |
| Genzyme Corporation | $13.88 | 2019 | |
| Mylan Specialty L.P. | $10.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danxuan Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.